NICE widens access to SGLT-2 inhibitors and GLP-1s in updated type 2 diabetes guidance
Newly diagnosed patients with type 2 diabetes mellitus (T2DM) should be offered a sodium–glucose co-transporter-2 (SGLT-2) inhibitor – which include dapagliflozin and empagliflozin – earlier in their treatment alongside metformin,…